Literature DB >> 8594632

Hyperlipofuscinosis and subretinal fibrosis in Stargardt's disease.

J J De Laey1, C Verougstraete.   

Abstract

BACKGROUND: The fundus aspect of Stargardt's disease is characterized by progressive atrophic macular changes often associated with fundus flavimaculatus flecks. Other fundus changes have been described such as pallor of the optic disc, attenuated retinal vessels, cicatricial chorioretinitis, retinal pigment hyperplasia, subretinal neovascularization, or subretinal fibrosis. Three cases of Stargardt's disease and presumed subretinal hyperlipofuscinosis or subretinal fibrosis are presented.
METHODS: The clinical history, and the ophthalmoscopic and fluoroangiographic characteristics of these three patients are discussed, as well as the clinical course in the two first patients.
RESULTS: Two young patients with the ophthalmoscopic and fluoroangiographic aspects of Stargardt's disease in one eye showed the presence of dense orange subretinal material in the posterior pole of the fellow eye. During the follow-up period, the abnormal material regressed partially in one patient and completely in the other, leaving subretinal fibrosis and localized retinal pigment epithelial hyperplasia. The left fundus in a third patient was characterized by an area of subretinal fibrosis in the midperiphery.
CONCLUSION: It is presumed that the abnormal material in the two first patients is lipofuscin and that this represents an exaggerated response of the diseased retinal pigment epithelium, possibly to a minor trauma. That material will eventually be replaced by subretinal fibrosis. The fundus appearance in the third patient is possibly the result of a similar process.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8594632     DOI: 10.1097/00006982-199515050-00005

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  12 in total

Review 1.  Retinoids for treatment of retinal diseases.

Authors:  Krzysztof Palczewski
Journal:  Trends Pharmacol Sci       Date:  2010-06       Impact factor: 14.819

2.  Metabolic basis of visual cycle inhibition by retinoid and nonretinoid compounds in the vertebrate retina.

Authors:  Marcin Golczak; Akiko Maeda; Grzegorz Bereta; Tadao Maeda; Philip D Kiser; Silke Hunzelmann; Johannes von Lintig; William S Blaner; Krzysztof Palczewski
Journal:  J Biol Chem       Date:  2008-01-14       Impact factor: 5.157

3.  ABCA4-associated retinal degenerations spare structure and function of the human parapapillary retina.

Authors:  Artur V Cideciyan; Malgorzata Swider; Tomas S Aleman; Alexander Sumaroka; Sharon B Schwartz; Marisa I Roman; Ann H Milam; Jean Bennett; Edwin M Stone; Samuel G Jacobson
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-12       Impact factor: 4.799

4.  The lipofuscin component A2E selectively inhibits phagolysosomal degradation of photoreceptor phospholipid by the retinal pigment epithelium.

Authors:  Silvia C Finnemann; Lawrence W Leung; Enrique Rodriguez-Boulan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

Review 5.  The molecular aspects of absorption and metabolism of carotenoids and retinoids in vertebrates.

Authors:  Made Airanthi K Widjaja-Adhi; Marcin Golczak
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2019-11-23       Impact factor: 4.698

Review 6.  Diseases caused by defects in the visual cycle: retinoids as potential therapeutic agents.

Authors:  Gabriel H Travis; Marcin Golczak; Alexander R Moise; Krzysztof Palczewski
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

7.  A non-retinoid antagonist of retinol-binding protein 4 rescues phenotype in a model of Stargardt disease without inhibiting the visual cycle.

Authors:  Boglarka Racz; Andras Varadi; Jian Kong; Rando Allikmets; Paul G Pearson; Graham Johnson; Christopher L Cioffi; Konstantin Petrukhin
Journal:  J Biol Chem       Date:  2018-06-05       Impact factor: 5.157

8.  Melanoregulin (MREG) modulates lysosome function in pigment epithelial cells.

Authors:  Monika Damek-Poprawa; Tanja Diemer; Vanda S Lopes; Concepción Lillo; Dawn C Harper; Michael S Marks; Yalin Wu; Janet R Sparrow; Rivka A Rachel; David S Williams; Kathleen Boesze-Battaglia
Journal:  J Biol Chem       Date:  2009-02-23       Impact factor: 5.157

9.  Epiretinal membrane removal in patients with Stargardt disease.

Authors:  Muna Bhende; Bindu Appukuttan; Ekta Rishi
Journal:  Indian J Ophthalmol       Date:  2015-01       Impact factor: 1.848

10.  Subretinal Fibrosis in Stargardt's Disease with Fundus Flavimaculatus and ABCA4 Gene Mutation.

Authors:  Settimio Rossi; Francesco Testa; Marcella Attanasio; Ada Orrico; Antonella de Benedictis; Michele Della Corte; Francesca Simonelli
Journal:  Case Rep Ophthalmol       Date:  2012-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.